UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):    May 4, 2016

 

	Endocyte, Inc.
	(Exact name of registrant as specified in its charter)

 

Delaware		001-35050		35-1969-140
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

 

3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana		47906
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code:

765-463-7175

 

	Not Applicable
	Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 4, 2016, Endocyte, Inc. (the “Company”) announced its results of operations for the three months ended March 31, 2016. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.

   

Item 9.01 Financial Statements and Exhibits.

 

(d)

Exhibits

 

99.1

Press Release dated May 4, 2016 relating to Endocyte’s first quarter 2016 results of operations.

 

The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Endocyte, Inc.
May 4, 2016	By:	/s/ Beth A. Taylor
		Name: Beth A. Taylor
		Title: Corporate Controller

 

 

Exhibit Index

 

Exhibit No.		Description
99.1		Exhibit 99.1 Earnings Release